Abstract Background: Exosomes are rich sources of biological material (proteins and nucleic acids) secreted by both tumor and normal cells, and found in urine of urinary bladder cancer patients. Objective: The objective of the study was to identify interacting exosomal proteins in bladder cancer for future use in targeted therapy. Methods: The Exocarta database (www.exocarta.org) was mined for urinary bladder cancer specific exosomal proteins. The urinary bladder cancer specific exosomal proteins (n = 248) were analyzed to identify enriched pathways by Onto-tool Pathway Express
Introduction
Exosomes are microvesicles shed by vesiculation events from various living cells secreted by most cell types, both cancerous and normal and secreted in biological fluids [1] and are thought to play important roles in intercellular communications. They are generated via diverse biological mechanisms triggered by pathways involved in oncogenic transformation, microenvironmental stimulation, cellular activation, stress, or death [2] . Biogenesis of the exosome begins with the secretion of signal peptide proteins in the cytoplasm. Intraluminal vesicles (ILVs) are formed through inward budding of endosomes to form multivesicular bodies (MVBs) or multivesicular endosomes (MVE). The MVB fuses with the cellular membrane, and the exosomes are released. MVBs can also be either degraded (by fusion with lysosomes) or recycled [3] . Although exosomes were originally described in 1983, interest in these vesicles has increased dramatically in the last few years, after the finding that they contain RNA, protein, lipid and other biomolecules [4] . It is clear that exosomes have specialized functions and play a key role in intercellular signaling and waste management. It is also well accepted that urinary exosomes (UEs) may be used as a novel biomarker source for early disease detection, classification, prediction severity, outcome and response to treatment [5] . Consequently, there is a growing interest in the clinical application of exosomes as it can potentially be used for prognosis, therapy, and as biomarkers for health and disease.
Cell-derived vesicles are released in many and perhaps all biological fluids, including blood [6] , urine [1] , breast milk [7] , malignant ascites [8, 9] , amniotic fluid [10] , bronchoalveolar lavage fluid [11] and culture medium supernatant in cell cultures [12, 13] . The content and secretion of these vesicles are dependent on cellular origin. It may be hypothesized that exosomes present in the urine may be secreted from any of the abdominal and pelvic organs such as the kidney, prostate, ovary, and urinary bladder. Studies were done on identification of exosomal proteins, since the first publication on proteomic profiling of UEs by Pisitkun et al., [1] while Mathivanan et al., [14] created a database, named ''Exocarta'' specifically for exosomes. Vesiclepedia database and urinary exosome protein database also contain information about exosomes, but these databases include those proteins which are also in the Exocarta database.
Urinary bladder cancer is the sixth most leading cancer in India and the second most common malignancy of the genitourinary tract [15] with a high recurrence rate. Urine cytology and cystoscopy along with biopsy are commonly used diagnostic and monitoring tools, but cytology has a sensitivity of only 29% [16] and cystoscopy is an invasive procedure. Hence, there is a diagnostic need of early detection markers which helps in surveillance of patients. Urinary exosomes may originate from the lining of the urinary tract, including glomerular podocytes, renal tubule cells, and urinary bladder. The number and content of UEs may change over time in association with disorders that affect the urinary system. Most of the membrane and cytoplasmic proteins of tumor cells will be excreted into urine by the process of endo and exocytosis making the microvesicles and exosomes a rich source of cancer-specific proteins [1, 2, 5] . Exosomes specifically secreted by the bladder lining or urinary bladder cancer cells into the urine may be the result of the interaction of some specific pathways. Identification of the interacting molecules of these pathways will identify targets of therapeutic interest and prevent tumor progression.
Data available on Exocarta database was analyzed using computational tools. Pathway based studies and system biology approach were performed to identify exosomal proteins specific to urinary bladder cancer. The present study identifies urinary bladder cancer-specific urinary exosomal proteins and analysis of their interactions revealed proteins which can be used as therapeutic targets. Exosomal proteins present in the urine were identified from the Exocarta database (www.exocarta.org) [1] . A seed list was prepared by selecting exosomal proteins specific only for bladder cancer. The 'seed list' was imported to the Pathway-Express module of Onto-tool (http://vortex.cs.wayne.edu/ projects.htm) and the pathways in which exosomal proteins were involved were identified [17] . Impact factor was calculated by the web-based software (Pathway-Express module) using both a statistically significant number of differentially expressed genes and biologically meaningful changes on a given pathway. Pathway-Express provides two types of p-values for each pathway: (i) p-value obtained using the classical statistics (referred to as classical p-value) and (ii) p-value obtained using the impact analysis (referred to as gamma pvalue). The classical p-value is calculated as an over-representation analysis using hypergeometric test. The gamma p-value is the p-value provided by the impact analysis [18] .
Methodology
Exosomal proteins involved in pathways with the high impact factor (cutoff >10), were selected for studying protein-protein interactions (PPIs) network and hubs. Proteinprotein interactions (PPIs) were commonly understood as physical contacts with molecular docking between proteins that occur in a cell or in a living organism in vivo [19] . Each of these interactions is specifically adapted to carry out certain biological functions. A PPI network is represented with proteins as nodes and interactions between nodes as the edges. The common proteins among top 9 pathways were further studied by a web-based software, POINeT (poinet.bioinformatics/tw). The number of iterations used was one i.e., only first degree neighbors of queried nodes were searched. The protein-protein interaction (PPI) information collected is integrated by various protein databases to provide PPI filtering and network topology analysis capability [20] . PPI was filtered for a number of literatures (>1), shared GO (Gene Ontology) terms (>1) and for interactors within the same species (Human). Graph centrality values average distance, index of aggregation, connectivity, cluster coefficient and degree of each subnetwork were computed.
The PPI network was visualized using the Cytoscape software (2.8.2 version) as an undirected graph in a force-directed layout [21] . It evaluated node essentiality by topological characters. The degree of a node was the number of links incident to this node in a network and identified hub nodes which are highly connected nodes in a network and vital for the proper function of a network [22] . Top 10 nodes ranked by degree scores were identified as hubs. Node centrality values were calculated in Cytoscape using the Network Analysis and cytoHubba plugin [23] . In network analysis, node color was based on Degree and intensity on Betweenness.
Results
A total of 4505 exosomal proteins are reported in the Exocarta database, of which 1152 were reported in the urine and 248 were reported specific to bladder cancer. The urinary bladder cancer specific exosomal proteins were taken as the seed protein list for identification of signaling pathways involved in exosome formation and secretion. Pathway-Express module from Onto-tools (http://vortex.cs.wayne.edu/ontoexpress) was used to identify the pathways which were most significantly involved. Impact factor was calculated by the Pathway-Express module and 9 Pathways having impact factor >10 were found to be significantly involved ( Fig. 2 and Table 1 ). Out of 248 bladder cancer specific exosomal proteins, 16 are involved in regulation of the actin cytoskeleton, 13 in tight junction, 14 in focal adhesion, 11 in leukocytes transendothelial migration, 8 in adherens junction, 8 in ECM receptor interaction, 13 in pathways in cancer, 6 in Shigellosis and 6 in Pathogenic Escherichia coli interaction pathways (Fig. 3) . These 9 pathways had a total number of 88 proteins, of which 14 were proteins interacting in more than one of the pathways and included A-catenin/CTNNA1, B-catenin/CTNNB1, Rho, RhoA, cdc42, ECM/MMRN1, Ras/N-Ras, Rac/ P21/PAK1, RTK/DDR1, VASP MLC/MLC1, ITGA4, PIK3C2A/MLCP and CTTNBP2/Cortactin (Table 2 ).
Protein-protein interaction network analysis and visualization in cytoscape
The 14 common proteins were used for graphic visualization of the network in Cytoscape. All protein-protein interactions showed one large network by CTNNA1, CTNNB1, VSAP, ITGA4, PAK1, DDR1, CDC42, RHOA, NRAS, RHO and PIK3AR1 and 3 small networks by MLC1, MMRN1, and CTTNBP2. In the large network, CDC42, CTNNB1, RHOA and PAK1 were hub proteins, showed maximum interaction with other proteins (Fig. 4) . Small hubs were formed by proteins VASP, KRAS, ITGA4, DDR1 and RHO, whereas PIK3C2A interacted only with PAK1 and CTNNB1 in a large network through EGFR. Hub proteins of the large network were connected by a number of inferred proteins. Feedback loops were formed by CTNNA1, DDR1, ITGA4, VASP, PAK1, RHOA and CDC42. All protein-protein interactions were complex due to a large number of interactions; hence the network was revisualized as filtered protein-protein interactions (filtered-PPI) (Fig. 5) . It showed 8 proteins in the network among 14 proteins. Among these MLC1, CTTNBP2 and MMRN1 were found to form small individual networks. In filtered-PPI, only 4 hub proteins were present (CTNNA1, CTNNB1, CDC42 and PAK1), in which direct interactions were found between CTNNB1 and CTNNA1; CDC42 and PAK1 whereas PAK1 and B-catenin interacted through inferred protein NF2. A-catenin and PAK1 formed a self loop in the large network. KRAS, RHOA, RHO and VASP formed smaller networks individually.
CytoHubba plugin was used to rank the proteins on the basis of four different centrality values -Degree, Betweenness, Closeness and Bottleneck (Table 3) . B-catenin, CDC42 and Filtered-PPI and centrality value showed B-catenin-PAK1-CDC42 had the highest sum of Degree, Betweenness, Closeness and Bottleneck. All three also interacted both with inferred protein NF2 and A-catenin. Hence, it was found that A-catenin, B-catenin, NF2, Pak1 and CDC42 are the most important proteins.
Discussion
Exosomes are highly complex nanometer-sized vesicles that are ubiquitous in biological systems. There is considerable interest to understand the physiological functions of exosomes in various cancers. Few studies of exosomes in various malignancies like prostate, breast, and colorectal cancers, melanoma, pleural mesothelioma, malignancies of the central nervous system, and others have been reported. The proteins associated with bladder cancer diseases could be detected on exosomes isolated from urine, indicating a possible use for urine exosomes as biomarkers [6, 13, 14] . For instance, Pisitkun et al. demonstrated the excretion of exosomes containing aquaporin-2 protein in autosomal dominant and autosomal recessive nephrogenic diabetes insipidus patients [1] . Similar proteomic studies performed on urinary exosomes generated molecular signatures, illustrating valuable potential for diagnostic, prognostic and pathophysiological discovery. Exosomes secreted by tumor cells are present in the urine and make a microenvironment in the bladder and may come in contact with the normal epithelial lining. While the mechanism of interaction of tumor and normal cells with exosomes is still not clear, it is possible that exosomes bind with specific ligands to cell surfaces. Upon binding, exosomes can enter target cells in one of two ways: by being taken up by the target cell's endocytic pathway or by fusing to the target cell's membrane and releasing its contents directly into the cytoplasm. Exosomes are increasingly recognized as mediators of intercellular communication due to their capacity to merge with and transfer a repertoire of bioactive molecular content (cargo) to recipient cells [24, 25] .
Exosomal proteins and gene expression have been reported to be increased in cancers and may be due to the secretion of exosomes at an increased rate by tumor cells undergoing active proliferation and invasion. The acquisition of a motile and invasive phenotype is an important step in the development of tumors and ultimately metastasis. This step requires the abrogation of cell-cell contacts, the remodeling of the extracellular matrix and of cell-matrix interactions, and finally the movement of the cell mediated by the regulation of actin cytoskeleton. The 9 pathways enriched included motility, cell to cell contact, metastasis receptor interaction and tumorigenesis. A-catenin and B-catenin are described to be associated with enhanced cell motility and cancer invasion, especially in patients with a cytoplasmic localization of this protein [26] . These cytoskeleton proteins may provide infrastructure for exosome formation and their cell to cell movement.
The tight junction is an intracellular junctional structure that mediates adhesion between epithelial cells and permeability across epithelial cell sheets. Microparticles or exosomes originated from leukocytes can induce differential effects on endothelial function and promote angiogenesis. The adherens junction is an element of the cell-cell junction in which Figure 5 Network diagram of the filtered PPI showing hub proteins CTNNB1, PAK1 and CDC42. Inferred protein NF2 is seen between CTNNB1 and PAK1.
cadherin receptors bridge the neighboring plasma membranes via their homophilic interactions. Cadherins associate with cytoplasmic proteins, called catenins, which in turn bind to cytoskeletal components, such as actin filaments and microtubules [27] . These molecular complexes further interact with other proteins, including signaling molecules. The regulatory mechanism of adherens junction may contribute to normal morphogenetic cell behavior as well as to the pathogenic one, such as cancer invasion and metastasis [28] . The extracellular matrix (ECM) consists of a complex mixture of structural and functional macromolecules and serves an important role in adhesion, migration, differentiation, proliferation, and apoptosis. 'Pathway in cancer' explains that cell growth and survival are regulated by complex signaling pathways that can be disrupted to cause cancer [29] . The pathway in cancer regulates cell proliferation, migration, apoptosis, and differentiation and any aberration in the pathway may cause uncontrolled cell growth. Almost 7 pathways explain the exosomal biogenesis, their specific secretion from tumorigenic environment. Proteins involved in Shigellosis and Pathogenic E. coli interaction pathways may explain their presence in urinary exosomes caused by bacterial infection found to occur frequently in these patients [30] .
Network analysis identified interacting proteins and subnetworks. The four proteins involved in the large network included B-catenin which is a component of the cadherin-based adherens junction complexes that form at cell-cell adhesion sites. Intracellular proteins like CD8 and CD9 (a protein present in exosome in almost all lower abdominal cancers), inhibit Wnt signaling and its inhibition reduces the cellular pool of B-catenin by enhancing the exosome-associated export of B-catenin from the cell [31] . A-catenin is a linking protein between cadherins and actin-containing filaments of the cytoskeleton are involved in the formation of exosomes. These proteins play a major role in the actin cytoskeleton, cell-cell adhesion and pathways in cancer. A-catenin and B-catenin interact with each other and form a cadherin-catenin complex which further activates and interacts with the known oncoproteins cdc42-rac1-pak1. cdc42 (a Cell division control protein 42 homolog) has a role in cell division in normal conditions, but in adverse conditions it is involved in exosomal complex formation by various pathways. Target molecules for Cdc42 have been identified to be p21-activated kinase. This gene encodes a family member of serine/threonine p21-activating kinases, known as PAK proteins. These proteins are critical effectors that link RhoGTPases to cytoskeleton reorganization and nuclear signaling, and they serve as targets for the small GTP binding proteins Cdc42 [32, 33] . A-catenin regulates cell proliferation by reducing B-catenin transcriptional activity, cdc42 and other oncogenes. It is also reported that loss of Bcatenin may cause prostate cancer [33] and bladder cancer.
NF2, interacting between B-catenin and PAK1, has been shown to act as a tumor suppressor primarily through its functions as a cytoskeletal scaffold. It also associates with a downstream effector of Rho small G proteins, which is associated with the formation of stress fibers and cytokinesis [34] .
The inferred protein NF2 was not reported in urine and may not be present in exosomes but their presence in cells may be necessary for the formation of exosomes or for cellular proliferation. NF2 causes a genetic disorder called neurofibromatoses that cause tumors to grow along nerves and produce other abnormalities such as skin changes and bone deformities [34] . Exact role of NF2 in bladder cancer patients is still not known but network analysis suggests a crucial role for this protein in the uncontrolled function of oncogene and cell cycle regulators. Targeted therapy at the check points by using drugs or monoclonal antibodies may block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. Bevacizumab (avastin) is an angiogenesis inhibitor used as a tumor growth inhibitor in colorectal cancer, rectal cancer, metastatic breast and lung cancer in combination with Capecitabine [35, 36, 37] . The presence of proteins in urinary exosomes likely to act with NF2 may suggest a role for Bevacizumab therapy in bladder cancer. Hence, we can use Bevacizumab therapy that might be useful as a targeted therapy against NF2 in urothelial cancer. However, further functional study to establish the role of this protein in bladder cancer should be accompanied by the role of Bevacizumab in suppressing tumor growth.
Conclusion
This preliminary analysis showed the presence of exosomal proteins alpha-catenin, beta-catenin, PAK1, CDC42 and inferred protein NF2 in the urine to be of importance in the biology of the tumor. However, the importance of these proteins in monitoring and therapy has to be elucidated on a large cohort of clinical samples. Targeted therapy of NF2 with monoclonal antibodies should also be explored for clinical application. CTNNB1  CTNNB1  CTNNB1 CTNNB1  CTNNB1  CDC42  CDC42  CDC42  CDC42  CDC42  RHOA  PAK1  PAK1  PAK1  PAK1  PAK1  RHOA  RHOA  RICS  RHOA  VASP  VASP  RICS  ERBB2  VASP  CTNNA1 KRAS  TGFBR1  FAS  CTNNA1  DDR1  ITGA4  PARD3  RHOA  DDR1  ITGA4  DDR1  IQGAP1  FLNA  ITGA4  KRAS  RHO  TRIP10  VCL  KRAS  RHO  RICS  PIK3R1  VASP  RHO 
